Mycophenolate mofetil (MMF; CellCept; Roche Laboratories) was developed as an alternative to azathioprine with reduced
myelotoxicity and hepatotoxicity and is now widely used in multi-drug regimes for prevention of human renal allograft
rejection (and more widely in transplantation medicine) and for
treating several human immune-mediated diseases